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Abstract:  
Tranexamic acid is an Hemostatic agent which acts by blocking the conversion of plasminogen to plasmin which is required in the 
formation of blood clot as shown in following diagram. It is Available in tablet, injection and Mouthwash form in market for the 
treatment of bleeding cases;  an  attempt  was  made  to prepare  and  evaluate Nasal spray containing  Tranexamic acid as  a  
Active ingredient  and Sodium CMC was used as mucoadhesive polymer to increase the contact time of formulation as , in nose 
bleeding the flow of blood is there and to avoid the washout of drug from site of action this is necessary to increase the contact 
time by increasing the viscosity of formulation by using the mucoadhesive polymer. and form artificial net to stop bleeding by 
trapping blood cells (RBC Etc.).Various formulations were prepared by using different concentrations of Sod. CMC and the best 
formulation were optimized by checking the spray property and contact time of each trial batch. The prepared Formulation were 
evaluated for their physicochemical parameters such as physical appearance, pH, Viscosity, Assay (drug content uniformity), In-
vitro permeation, Spray property, In-vitro permeation, Droplet size distribution, Pump Delivery, and contact time. A 61 full factorial 
design was applied to the formulations containing different concentration of polymer . From factorial design batches (F0-F5) the 
batch with Good sprayability and higher contact time(F3) were considered as optimized batch. Finally it can be concluded that 
the nasal spray of tranexamic acid were formulated and evaluated successfully for treatment of epistaxis, Accidental and operative 
bleeding. 
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INTRODUCTION: 
The Rational behind the formulation of this nasal 
spray is that the Tranexamic acid (TXA) is a synthetic 
derivative of the amino acid lysine, which inhibits 
fibrinolysis by blocking the lysine-binding site of 
plasminogen. Currently, it is one of the most 
commonly used haemostatic drugs and is capable of 
reducing blood loss volume in surgical 
patients, Moreover, this drug has effectively reduced 
the blood loss volume in various surgical settings, 
including in traumatic haemorrhage, caesarean 
section, and cardiac surgeries. The tremendous 
Clinical trials are carried out by different 
Organisations to determine the efficacy of tranexamic 
acid applied locally to control bleeding and available 
on the website U.S. Library of medicine : 
ClinicalTrials.gov and they determined its external 
efficacy and the no side effect as internal medicines 
have the side effect of Thrombosis ( Internal blood clot 
formation and embolism ). Tranexamic acid Is now 
available in Tablet, Injectable, Mouthwash Dosage 
forms to stop bleeding and Bathing Soap (Skin 
whitening). The 5 % mouthwash of tranexamic acid 
are now recently coming into the market for the patient 
on which the Mouth surgery (Ex. Tooth Extraction) 
carried out ; the Two pharmacy also make its own 
Mouthwash to stop bleeding in dental surgery in 
patient having coagulation defects. The Monograph of 
Tranexamic acid Mouthwash also made available for 
testing by British Pharmacopoeia commission. A 
tranexamic acid solution can be used before a 
procedure to prevent bleeding in patients with 
bleeding disorders. The solution is used as a rinse by 
the patient for about 2 minutes, a half hour before a 
procedure. Tranexamic acid can also be used after the 
procedure and as needed in emergency 
situations.  After an oral procedure a solution can be 
used by the patient every one to two hours to control 
bleeding. It should be held in the mouth by the patient 
and not “swished” as this can dislodge a clot. In tablet 
form, antifibrinolytic medications are available under 
different brand names. They are prescribed for patients 
who have blood clotting disorders and are having 
minor surgery. In the case of oral surgery however, 
taking a tablet is not ideal for these patients. Topical 
administration of tranexamic acid with a rinse inhibits 
clot breakdown locally while minimizing systemic 
effects. For patients who have coagulation disorders 
and are on medications like warfarin, reducing 
systemic effects can be crucial.  A tranexamic acid 
mouth rinse results in a lower plasma concentration 
than a tablet while effectively controlling bleeding. 
The Rationale behind use of Sodium CMC was; It is 
found as mucoadhesive polymer and tremendously 
used in to the Eye drops (Artificial Tears) 
Manufacturing . So I decided to use this polymer in my 
formulation to increase the contact time of formulation 
as , in nose bleeding the flow of blood is there and to 
avoid the washout of drug from site of action this is 
necessary to increase the contact time by increasing 
the viscosity of formulation by using the 
mucoadhesive polymer. 
MATERIALS AND METHODS: 
Table no.: 01: List Of Chemicals: 
Sr. 
No. 
Name of the Chemicals Category Manufacturer / Supplier 
1 Tranexamic Acid API Shilpa Medicare Limited 
Raichur ,Karnataka 
2 Sodium CMC Polymer Lucid Colloids Ltd. 
3 Sodium Metabisulphite Antioxidant Halogens Tundav,Vadodara 
4 Monopotassium Phosphate Buffer 
system 
Halogens Tundav,Vadodara 
5 Disodium Hydrogen 
Phosphate 
Buffer 
system 
Halogens Tundav,Vadodara 
6 Sodium Methyl Paraben Preservative Nebula Healthcare Ankhol, 
Gujarat. 
7 Methanol (HPLC) Solvent Merck Life sciences 
Mumbai 
8 Triethylamine (HPLC) Solvent SDFCL Mumbai 
9 Perchloric Acid 70 % Reagent Loba Chemie Pvt Ltd. 
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Table No.2: List of Instruments: 
Sr. No. Name of the Instrument Model/Make 
1 Analytical weighing balance  Shimadzu (AUX220)  
2 UV Vis-Spectrophotometer  Shimadzu (UV-1800)  
3 ATR spectrophotometer  Shimadzu, Japan  
4 TOC Analyzer Shimadzu 
5 Magnetic Stirrer  Remi Equipments, Mumbai.  
6 Sonicator Citizen.  
7 Hot Air Oven Thermolab, Mumbai 
9 Viscometer Brookfield viscometer 
10 Digital PH meter  Toshniwal instruments 
Ajmer  
11 Stability chamber  Thermolab, Mumbai.  
12 Franz Diffusion Apparatus  Orchid  
13 HPLC Agilent Technologies 
(1120 Compact LC) 
14 Melting point Apparatus Thermocal 
 
Preformulation Study: 
 
Identification tests: 
Identification Test Pharmacopoeial Standard Observed Result 
Appearance Crystalline Crystalline 
Colour White Or Almost White White 
Odour Odourless Odourless 
 
Solubility: 
 
Solvent Pharmacopoeial Standard Observed Solubility 
Water Freely soluble  Freely soluble  
Phosphate Buffer pH 6.8 Freely soluble Freely soluble 
Glacial Acetic Acid Freely soluble Freely soluble 
Acetone Practically Insoluble Practically Insoluble 
Ethanol (96 %) Practically Insoluble Practically Insoluble 
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FTIR Spectrophotometric Analysis: 
The infrared absorption spectrum, Of sample matched with the spectrum given into the Indian Pharmacopoeia and 
found identical to each other. 
 
 
 
 
FTIR Spectra of Tranexamic acid 
 
 
 
IR Spectra of Tranexamic acid As specified in IP 2014 
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Calibration curve of Tranexamic acid by RP-HPLC 
 
Table No: 3 Factorial design of batches for Optimization: 
 
Formulation  Ingredients 
Formulation Codes 
F0 F1 F2 F3 F4 F5 
Tranexamic Acid 5 % 5 % 5 % 5 % 5 % 5 % 
Sodium CMC 0.0 % 0.1 % 0.3 % 0.5 % 0.7 % 0.9 % 
Sodium Metabisulphite 0.1 % 0.1 % 0.1 % 0.1 % 0.1 % 0.1 % 
Monopotassium Phosphate 
0.0301 
% 
0.0301 
% 
0.0301 
% 
0.0301 
% 
0.0301 
% 
0.0301 
% 
Disodium Hydrogen Phosphate 
0.050 
% 
0.050 
% 
0.050 
% 
0.050 
% 
0.050 % 0.050 % 
Sodium Methyl Paraben 0.2 % 0.2 % 0.2 % 0.2 % 0.2 % 0.2 % 
Purified Water 
Q.s.to 
100 % 
Q.s.to 
100 % 
Q.s.to 
100 % 
Q.s.to 
100 % 
Q.s.to 
100 % 
Q.s.to 
100 % 
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General Procedure for Preparation of Nasal Spray: 
1) Manufacturing of Bulk solution : 
➢ 80% Of vehicle / solvent (Purified Water) are 
taken into Mfg. Tank and require to Flush 
Nitrogen as inert gas for 15 min. to remove 
dissolved gases from vehicle. 
➢ Add and dissolve the Preservative (Sodium 
Methyl Paraben) into above solution. 
➢ Add and Dissolve the Antioxidant (Sodium 
Metabisulphite) into it and stir well 
continuously with continue Nitrogen 
spurging into solution with SS Tubing, tube 
should reach upto the Bottom of Mfg. Tank. 
➢ Add and Dissolve the Buffer contributing 
ingredients (Monopotassium Phosphate 
and Disodium Hydrogen Phosphate). 
➢ Check the pH Of above solution ,it should be 
near to the pH at which active material stable. 
➢ Then add and Dissolve Active Material 
(Tranexamic Acid)and stir well. 
➢ Then add and dissolve the any other 
Viscosity modifying ingredient (Sodium 
CMC) ; it is good to make slurry into small 
amount of vehicle at 45 to 50 0C and then 
transfer to the main Batch with stirring. 
➢ The remaining 20% Vehicle will be used for 
the Rinsing purpose and volume makeup. 
➢ Make up the final volume with remaining 
Solvent/vehicle. 
2) Filling Of Manufactured Bulk into Spray 
Bottle : 
➢ Plastic Squeeze Type plastic Spray bottle are 
used for the Filling of bulk supplied from SSF 
Plastic Pvt. Ltd. Bhimpore, Dalama, Daman 
and Diu. 
➢ Supplied Bottles are washed before filling 
and dried. 
➢ The manufactured Bulk was filled into the 
Squeeze type spray bottle (10ml) with pre 
and post Nitrogen Flushing and instantly the 
Straw type plug and cap  was fixed . 
 
 EVALUATION OF NASAL SPRAY OF 
TRANEXAMIC ACID: 
1) Description of formulated solution. 
2) E.g. Colour, Odour, State etc. 
3) Viscosity 
4) Density of formulation. 
5) Sprayability / Spray Property 
6) pH of Formulation 
7) Assay 
8) In-vitro permeation. 
9) Droplet size distribution. 
10) Pump Delivery. 
11) Skin Irritation Study. 
12) Contact time / Mucoadhesive strength. 
13) Stability study of optimized formulation 
of Tranexamic Acid. 
 
Table 4. Evaluation Table: 
 
Sr. No 
Formulation 
Code 
Description 
Of  Formulation 
Viscosity 
(Cp) 
Density 
(gm/ml) 
pH 
01 F0 Clear , Colourless Solution 1 1.01 7.05 
02 F1 Clear , Colourless Solution 21.55 1.02 7.1 
03 F2 Clear , Colourless Solution 37.2 1.02 7.2 
04 F3 Clear , Colourless Solution 63.5 1.04 7.2 
05 F4 Clear , Colourless Solution 120.3 1.05 7.3 
06 F5 Clear , Colourless Solution 200.1 1.05 7.2 
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Assay of formulations by RP-HPLC  
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5. Evaluation Table: 
 
 
Sr. No. 
Formulation 
Code 
Area 
Assay 
(mg/ml) 
Assay 
(%) 
Standard 
(1000 ppm) 
Test / Sample 
01 F0 
334440 
334849 48.19 96.38 
02 F1 334010 48.31 96.62 
03 F2 333982 48.32 96.64 
04 F3 330123 48.88 97.76 
05 F4 333150 48.44 96.88 
06 F5 330515 48.82 97.64 
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Table 6. Evaluation Table: 
 
 
 
 
 
 
 
 
 
Pump Delivery :  
Table 7. Evaluation Table: 
 
 
 
 
 
 
 
 
Sr. No. Formulation Code 
Mucoadhesive Strength 
(gm) 
01 F0 0.89 
02 F1 1.10 
03 F2 1.45 
04 F3 1.79 
05 F4 2.91 
06 F5 3.89 
Sr. No. 
Initial Gross Wt of 
spray 
Gross Wt. After 
Spray Delivery 
Net Volume (Gm) 
Ejected 
1 28.21 27.76 0.45 
2 27.76 27.39 0.37 
3 27.39 27.09 0.30 
4 27.09 26.78 0.31 
5 26.78 26.45 0.33 
Mean of pump delivery 0.35 
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• Droplet Size Distribution : 
Table No 8.: Droplet Size Distribution 
Height 
(cm) 
Size of Droplet (mm) 
Mean 
1 2 3 4 5 6 7 8 9 10 
3 1 0.41 1 0.45 1 1 0.83 0.87 1 1 0.97 
6 0.15 1 1 0.75 1 1 0.95 0.91 1 84 0.86 
10 1 0.87 1 0.83 1 0.38 1 0.70 1 1 0.88 
Mean Droplet Size 0.9 
The droplet size ejected by formulation was bigger that is important in case of Bleeding to deliver more formulation. 
STABILITY STUDIES: 
Table 9. Evaluation Parameters of Formulation F3 during stability study 
 
Sampling Time 
Interval 
(Month) 
Description 
Of  Formulation 
Viscosity 
(Cp) 
Density 
(gm/ml) 
pH 
Assay 
(%) 
Initial 
Clear , Colourless 
Solution 
63.5 1.04 7.2 97.46 
1 
Clear , Colourless 
Solution 
64.2 1.02 7.1 96.38 
3 
Clear , Colourless 
Solution 
63.8 1.03 7.2 98.62 
6 
Clear , Colourless 
Solution 
64.5 1.04 7.3 96.64 
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RESULT AND DISCUSSION: 
The aim of present investigation was to develop 
Formulation Of Tranexamic Acid  Nasal Spray For 
Treatment Of Intranasal Bleeding and blood loss in 
Epistaxis and Accidental conditions. The pre-
formulation study was performed for both drug and 
excipients.  The compatibility study between 
Tranexamic Acid and excipients was ascertained by 
FTIR and Assay of Physical Mixture. The Different 
Batches was prepared and concentrations of 
Excipients were optimized. Sodium CMC was used as 
Polymer to increase the contact time of formulation 
with damaged skin. A 61 full factorial design was 
applied to Optimize concentration of Sodium CMC, 
The Modified balance was used to study the contact 
time of developed formulations. The Formulation 
were evaluated for parameters such as Description of 
formulated solution, E.g. Colour, Odour, State etc. 
Then Viscosity, Density of formulation, Sprayability / 
Spray Property, pH of Formulation, Assay, Skin 
Irritation Study, In-vitro permeation, Droplet size 
distribution, Pump Delivery, Contact time / 
Mucoadhesive strength etc. The 6 months Stability 
study of optimized formulation of Tranexamic Acid 
was carried out and found stable. 
 
CONCLUSION: 
• Optimized Nasal spray (F3) showed the desired 
characteristics that should have for intranasal 
products. 
• Optimized formulations (F3) have Good 
Sprayability and the longer contact time; which 
may not washout during flow of blood. 
• Optimized formulations (F3) Showed the same 
Sprayability in comparative study with Marketed 
formulation. 
• As mentioned above the F3 batch was Optimised  
due to its Good Sprayability and longer contact 
time. 
• It is found that as concentration of Sod. CMC 
Increases the Spray property decreases so lower 
concentration having good sprayability batch 
was optimized. 
• The no compatibility issue was observed in 
batches as per Stability analysis data. 
• From the result of 21 Day Skin irritation study; it 
is concluded that the no Side effects of 
formulation was there. 
• Finally it can be concluded that the Formulation 
Of Tranexamic Acid  Nasal Spray For Treatment 
Of Intranasal Bleeding and blood loss in 
Epistaxis and Accidental conditions was 
Successfully developed. 
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